Why the study?
Does leukaemic cell burden influence the plasma concentrations of daunorubicin in patients with acute myeloid leukaemia?
Population
40 patients with acute myeloid leukaemia
Design
Cohort
Follow-up
24 hours
Authors
Loading...
Weak inverse WBC-DNR association in AML; hypothesis-generating and leaves open dosing implications.
Does leukaemic cell burden influence the plasma concentrations of daunorubicin in patients with acute myeloid leukaemia?
A large leukaemic cell burden lowers the plasma concentration of daunorubicin in patients with acute myeloid leukaemia, suggesting dose adjustments may be necessary for patients with high WBC counts.
Bogason et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: